^
Association details:
| Biomarker: | KMT2A-PTD |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + decitabine (DNMT inhibitor) + Zolinza (vorinostat) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
Excerpt:
Six of 17 patients achieved complete remission including 2 of 4 patients with KMT2A partial tandem duplication. Combination therapy with decitabine, vorinostat and cytarabine was tolerated in younger relapsed/refractory acute myeloid leukemia and should be explored
DOI:
10.3324/haematol.2017.186890
